Ipidacrine Grindeks (Ipidacrine Hydrochloride)

Ipidacrine reversibly inhibits acetylcholinesterase, the enzyme that degrades acetylcholine. By blocking this enzyme, the drug raises acetylcholine levels at neuromuscular junctions and in the brain, enhancing muscle contraction and cholinergic neurotransmission, which can improve muscle strength and cognitive function.

The dosage of Ipidacrine is individualized. A qualified prescriber determines the appropriate dose based on the patient’s condition, response, and tolerability, following local prescribing guidelines.

Safety data for Ipidacrine in pregnancy and lactation are limited. It should be used only if the potential therapeutic benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

The primary alternative for myasthenia gravis is pyridostigmine, another acetylcholinesterase inhibitor. Ipidacrine has a longer half‑life and may be preferred in patients who require less frequent dosing, but both share similar efficacy and safety profiles, with individual tolerability guiding choice.

Ipidacrine tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep out of reach of children and do not use after the expiry date.

Ipidacrine is administered orally as a tablet, usually taken with a glass of water. The prescriber may advise taking it with or without food depending on individual tolerance.

Serious risks include hepatotoxicity, severe cholinergic crisis, cardiac arrhythmias, worsening muscle weakness, and allergic reactions such as rash or anaphylaxis. Patients should seek immediate medical attention if they experience signs of liver injury, chest pain, severe muscle fatigue, or allergic symptoms.

Ipidacrine is contraindicated in patients with known hypersensitivity to the drug, severe hepatic impairment, or those taking other potent acetylcholinesterase inhibitors. Caution is also advised for individuals with uncontrolled cardiac disease or active cholinergic crisis.